Simona Carlomagno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10966487/publications.pdf

Version: 2024-02-01

32 papers

2,589 citations

331259 21 h-index 32 g-index

32 all docs 32 docs citations

32 times ranked 3632 citing authors

#	Article	IF	CITATIONS
1	CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10116-10121.	3.3	412
2	NK-dependent DC maturation is mediated by TNFî \pm and IFNî 3 released upon engagement of the NKp30 triggering receptor. Blood, 2005, 106, 566-571.	0.6	365
3	The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood, 2006, 108, 4118-4125.	0.6	323
4	The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. European Journal of Immunology, 2003, 33, 1657-1666.	1.6	229
5	The small subset of CD56brightCD16– natural killer cells is selectively responsible for both cell proliferation and interferon-l³ production upon interaction with dendritic cells. European Journal of Immunology, 2004, 34, 1715-1722.	1.6	178
6	Features of Memory-Like and PD-1+ Human NK Cell Subsets. Frontiers in Immunology, 2016, 7, 351.	2.2	107
7	Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood, 2011, 117, 4284-4292.	0.6	104
8	A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood, 2010, 116, 1637-1647.	0.6	83
9	TLR/NCR/KIR: Which One to Use and When?. Frontiers in Immunology, 2014, 5, 105.	2.2	77
10	Human NK cell response to pathogens. Seminars in Immunology, 2014, 26, 152-160.	2.7	71
11	Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. European Journal of Immunology, 2006, 36, 961-967.	1.6	67
12	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. Frontiers in Immunology, 2019, 10, 1415.	2.2	57
13	NK Cell-Based Immunotherapy for Hematological Malignancies. Journal of Clinical Medicine, 2019, 8, 1702.	1.0	54
14	Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?. Frontiers in Immunology, 2015, 6, 573.	2.2	51
15	Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. Frontiers in Immunology, 2020, 11, 2156.	2.2	49
16	KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts. Blood, 2013, 121, 3396-3401.	0.6	46
17	NK/DC Crosstalk in Anti-viral Response. Advances in Experimental Medicine and Biology, 2012, 946, 295-308.	0.8	36
18	Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncolmmunology, 2015, 4, e1052353.	2.1	34

#	Article	IF	CITATIONS
19	Bridging Innate NK Cell Functions with Adaptive Immunity. Advances in Experimental Medicine and Biology, 2011, 780, 45-55.	0.8	32
20	Heterogeneity of TLR3 mRNA transcripts and responsiveness to poly (I:C) in human NK cells derived from different donors. International Immunology, 2007, 19, 1341-1348.	1.8	26
21	miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2020, 8, 119.	1.8	26
22	NK cells and their receptors during viral infections. Immunotherapy, 2011, 3, 1075-1086.	1.0	25
23	KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing. Frontiers in Immunology, 2017, 8, 581.	2.2	24
24	Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation. Journal of Leukocyte Biology, 2011, 90, 661-667.	1.5	21
25	Uptake of CCR7 by KIR2DS4+NK Cells Is Induced upon Recognition of Certain HLA-C Alleles. Journal of Immunology Research, 2015, 2015, 1-10.	0.9	21
26	Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis. Frontiers in Immunology, 2019, 10, 1963.	2.2	21
27	NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles. Seminars in Hematology, 2020, 57, 175-184.	1.8	10
28	Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance. Cancers, 2020, 12, 3705.	1.7	10
29	NK Cell-Based Immunotherapy in Colorectal Cancer. Vaccines, 2022, 10, 1033.	2.1	10
30	CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2022, 13, 837457.	2.2	9
31	CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells. Blood, 2018, 132, 3491-3491.	0.6	8
32	Natural killer cell impairment in ovarian clear cell carcinoma. Journal of Leukocyte Biology, 2020, 108, 1425-1434.	1.5	3